Rocket Pharmaceuticals gets FDA RMAT status for heart disorder therapy
Source: SeekingAlpha
2025-07-17 09:13:39 ET
More on Rocket Pharmaceuticals
- Rocket Pharmaceuticals: Despite FDA Clinical Hold On RP-A501, Prospects Remain Intact
- Rocket Pharma plunges after FDA clinical hold on mid-stage trial
- Seeking Alpha’s Quant Rating on Rocket Pharmaceuticals
- Historical earnings data for Rocket Pharmaceuticals
- Financial information for Rocket Pharmaceuticals
Read the full article on Seeking Alpha
For further details see:
Rocket Pharmaceuticals gets FDA RMAT status for heart disorder therapy
Rocket Pharmaceuticals Inc.
NASDAQ: RCKT
RCKT Trading
-7.97% G/L:
$4.275 Last:
2,683,203 Volume:
$4.55 Open:
RCKT Latest News
July 17, 2025 07:00:00 am
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy
July 09, 2025 05:16:00 pm
Berger Montague PC Investigates Rocket Pharmaceuticals (RCKT) Over Safety Disclosures and Stock Drop
RCKT Stock Data
$350,640,019
77,378,893
1.77%
48
N/A
Biotechnology & Life Sciences
Healthcare
US
Cranbury
